Search Hotels in Sausalito

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

Topics Government World Trade

September 25, 2025

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was...

Topics Government

Eli Lilly (LLY) Stock Trades Down, Here Is Why

September 25, 2025

Via StockStory

Topics Artificial Intelligence

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? ↗

September 25, 2025

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it...

Via Benzinga

AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection

September 25, 2025

In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July...

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Topics Artificial Intelligence

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗

September 25, 2025

Via Benzinga

Does This Acquisition Make Pfizer Stock a Great Buy? ↗

September 25, 2025

There's an opportunity to get in on the weight-loss drug craze at a reasonable price.

The latest data from the company's oral weight loss drug is bullish for the stock.

Topics Death Intellectual Property

1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today ↗

September 25, 2025

Topics Economy

Eli Lilly Terminates Study Of Bimagrumab In Obesity ↗

September 25, 2025

Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. ↗

September 25, 2025

Investors once speculated that Pfizer might consider acquiring Viking.

Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas ↗

September 23, 2025

Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick ↗

September 22, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Topics Intellectual Property

3 Small-Cap Stocks We Keep Off Our Radar

September 25, 2025

Via StockStory

Healthcare Sector Grapples with 5% Slump in 2025: A Deep Dive into Market Underperformance

September 24, 2025

The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year...

Once up and running, it and other projects should make the company's supply chain stronger.

Topics Artificial Intelligence ETFs Economy

Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy? ↗

September 24, 2025

Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines.

Topics Artificial Intelligence Economy

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO ↗

September 24, 2025

Via Benzinga

Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset ↗

September 24, 2025

Via Benzinga

Topics ETFs

STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy

September 23, 2025

STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights...

The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.

Topics Intellectual Property

The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗

September 23, 2025

Via Benzinga

What's Pfizer Getting in Its $7.3 Billion Metsera Buyout? ↗

September 23, 2025

Pfizer's plan to enter the booming obesity market took an expensive new turn.

Tech did the heavy lifting as Nvidia and Apple dragged indexes over the finish line; gold hit yet another all-time high while oil sagged. The Fed chorus grew louder and more discordant.

Nvidia’s $100B Bet in OpenAI Pushes Wall Street to Fresh Records ↗

September 23, 2025

Via Chartmill

Topics Economy

Unpacking the Latest Options Trading Trends in Eli Lilly ↗

September 22, 2025

Via Benzinga

Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape

September 22, 2025

As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating...

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Topics Artificial Intelligence Economy Intellectual Property

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Topics Economy Intellectual Property

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Via Benzinga

Healthcare Sector Outlook: Navigating Regulatory Headwinds and Breakthrough Innovations

September 22, 2025

The healthcare sector is currently experiencing a period of profound transformation, marked by a fascinating dichotomy: groundbreaking medical innovations are driving unprecedented growth for some,...

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Topics Artificial Intelligence Earnings Economy

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity...

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron

September 22, 2025

NVIDIA's AI Engine Roars On: Data Center Dominance Fuels Stellar Q2, But Market Seeks More

Topics Economy

September 22, 2025

NVIDIA (NASDAQ: NVDA) continues to be the undisputed titan in the artificial intelligence arena, recently unveiling a dazzling Q2 fiscal year 2026 earnings report that underscored its foundational role...

The drugmaker continues to lead the increasingly competitive market for weight management drugs.

Topics Artificial Intelligence Earnings Economy

Is Eli Lilly Stock a Buy After Gaining 10% in 1 Month? ↗

September 22, 2025